Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334352 | 0.92 | CYP2A6 (0.39) | CYP11B1CYP11B2MAOAMAOBALDH1A1 | |
| SCHEMBL9778974 | 0.83 | MAOB (0.53) | MAOAMAOBKCNH2 | |
| SCHEMBL9451018 | 0.82 | MEN1 (0.41) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL10591118 | 0.80 | CA2 (0.37) | MAOAMAOBALDH1A1CYP2A6CA12 | |
| SCHEMBL92259 | 0.80 | GABRP (0.38) | CYP11B1CYP11B2CA12CA2CA9 | |
| SCHEMBL1780656 | 0.78 | DRD2 (0.50) | CYP11B1CYP11B2ALDH1A1CYP19A1 | |
| SCHEMBL31442 | 0.77 | ALDH1A1 (0.39) | CYP11B2ALDH1A1CYP2A6CA12CA2 | |
| SCHEMBL13014690 | 0.77 | KCNH2 (0.44) | CYP11B1CYP11B2MAOAMAOBCYP19A1 | |
| SCHEMBL9627406 | 0.77 | CA2 (0.39) | ALDH1A1CYP2A6CA12CA2CA3 | |
| SCHEMBL9906430 | 0.76 | KCNH2 (0.46) | CYP11B1CYP11B2MAOAMAOBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57102981-A | — | — | None | — | — | JP | disclosed |
| WO-2025125811-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Ontrack Therapeutics Limited (GB) | 2025-06-19 | — | — | WO | disclosed |
| EP-3541368-B1 | IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF | US HEALTH (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3541368-B1 | IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF | US HEALTH (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3802730-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-04-19 | — | — | EP | disclosed |
| US-11382990-B2 | Imageable polymers, methods of making and methods of use thereof | THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382990-B2 | Imageable polymers, methods of making and methods of use thereof | THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3529333-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| EP-3529332-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| US-20200197540-A1 | Imageable Polymers, Methods of Making and Methods of Use Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-06-25 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| JP-S57102981-A | NEMATIC LIQUID CRYSTAL COMPOSITION | SEIKO EPSON CORP | 1982-06-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | CYP11B1 1177/4885CYP11B2 1052/4885MAOA 939/4885 |
| US-11382990-B2 | Imageable polymers, methods of making and methods of use thereof | PUF60, PBRM1, PCBP1 | CYP11B1 4071/4885CYP11B2 4158/4885MAOA 3360/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | CYP11B1 315/4885CYP11B2 314/4885MAOA 372/4885 |
| US-20200197540-A1 | Imageable Polymers, Methods of Making and Methods of Use Thereof | PUF60, PBRM1, PCBP1 | CYP11B1 4071/4885CYP11B2 4158/4885MAOA 3360/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | CYP11B1 1277/4885CYP11B2 1125/4885MAOA 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.